ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review "
Episode Synopsis
Host: Caitlin Costello, MD
Guest: Sagar Lonial, MD, FACP
Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.
More episodes of the podcast Global Oncology Academy
ATTR Amyloidosis: Familial Vs Wild-Type
23/04/2024
The Multiple Faces of ATTRv-PN
23/04/2024
Diagnosing ATTRv-PN: What's in Your Toolbox?
23/04/2024
Shh…Gene-Silencing Therapies for ATTRv-PN
23/04/2024
ATTRv-PN: A Family Affair?
23/04/2024
In God we trust